Question explored with the scientific record
Liver side effects of long term tamoxifen
The short version: tamoxifen causes fatty liver disease in a large fraction of women who take it, and the evidence for this is consistent across animal models and human studies.
The question is about liver side effects of long-term tamoxifen. The evidence is clear on mechanism and prevalence. A 2020 meta-analysis of 24 studies found that about 40 in 100 breast cancer patients on tamoxifen develop fatty liver, with an incidence rate about 3 times higher than in women not taking it [7]. A 2017 propensity-matched cohort of 328 women found tamoxifen users had a hazard ratio of 1.61 for new fatty liver compared to women on aromatase inhibitors [11]. A 2021 study of 308 patients confirmed this, showing tamoxifen also increases liver fibrosis markers [19].
The mechanism is well-documented in animal work. Tamoxifen disrupts mitochondrial function and depletes mitochondrial DNA in mouse liver [17]. It increases hepatic triglyceride synthesis while suppressing fat oxidation [16]. A 2026 study in mice showed tamoxifen depletes a protective bile acid (hyodeoxycholic acid) by altering gut bacteria, which disrupts liver bile acid signaling and causes injury [4]. Multiple rat studies show tamoxifen raises liver enzymes (ALT, AST) 2-4 fold and causes oxidative stress, steatosis, and inflammation [1, 3, 5, 6].
The human data is mostly observational, not from randomized trials designed to track liver outcomes. The meta-analysis notes high heterogeneity (I²=84%) [7], meaning the true rate varies by population and detection method. Risk factors include higher BMI and pre-existing high cholesterol [7].
| Group | Fatty liver incidence | Key comparison |
|---|---|---|
| Tamoxifen users (meta-analysis) | ~40% prevalence | 3.12x higher than non-users [7] |
| Tamoxifen vs aromatase inhibitors | 128.7 vs 81.1 per 1000 person-years | HR 1.61 [11] |
| Tamoxifen vs toremifene | 113.2 vs 67.2 per 1000 person-years | Toremifene HR 0.55 for fatty liver [19] |
My call: tamoxifen causes fatty liver disease in a substantial minority of users, with risk increased by obesity and high cholesterol. The mechanism is biologically plausible and replicated across species. The evidence is moderate quality—consistent but mostly observational. Confidence: moderate.
Sources examined 20
-
Zafirlukast and vincamine ameliorate tamoxifen-induced oxidative stress and inflammation: Role of the JNK/ERK pathway
Zafirlukast and vincamine mitigate tamoxifen-induced liver injury in female rats by inhibiting the JNK/ERK signaling pathway and NF-κB–mediated inflammatory responses, reducing oxidative stress and boosting anti-inflammatory IL-10.
DOI: 10.1016/j.lfs.2018.04.002 -
LIVER ENZYMES
A cross-sectional study of 47 female breast cancer patients in Karachi, Pakistan, comparing liver enzyme changes during cancer treatment between those with diabetes and those with cardiac comorbidities, finding post-treatment increases in alkaline phosphatase and variable ALT el…
DOI: 10.29309/tpmj/2015.22.06.1242 -
Nebivolol effect on oxidative biomarkers in Tamoxifen-Induced Hepatotoxicity in Female White Albino Rats: In Vivo Study
Nebivolol pretreatment protects against tamoxifen-induced hepatotoxicity in female rats by upregulating hepatic GPx and reducing malondialdehyde (MDA) in a dose-dependent manner.
DOI: 10.32947/ajps.v25i2.1157 -
Tamoxifen induced hepatotoxicity via gut microbiota-mediated hyodeoxycholic acid depletion and Farnesoid X receptor signaling disruption
Tamoxifen induces liver injury in mice via gut microbiota–mediated depletion of hyodeoxycholic acid (HDCA) and disruption of gut-liver FXR signaling, an effect that can be mitigated by HDCA or FXR-modulating therapies and is shown to involve microbial changes, bile acid metaboli…
DOI: 10.1080/19490976.2025.2610077 -
Allicin enhances chemotherapeutic response and ameliorates tamoxifen-induced liver injury in experimental animals
This study investigates the effects of allicin on enhancing the chemotherapeutic response of tamoxifen while mitigating its hepatotoxic effects in experimental animal models.
DOI: 10.3109/13880209.2013.876053 -
Protective potential of bempedoic acid as an AMPK activator in tamoxifen-induced steatohepatitis in rats
Bempedoic acid activates AMPK to mitigate tamoxifen-induced steatohepatitis in female rats by reducing oxidative stress and inflammation and rebalancing hepatic lipid metabolism toward fatty acid oxidation, thereby improving liver histology and biochemical markers.
DOI: 10.1007/s00210-025-04047-5 -
Prevalence, incidence and risk factors of tamoxifen‐related non‐alcoholic fatty liver disease: A systematic review and meta‐analysis
This study systematically reviews and meta-analyzes published data to determine how common and how frequent tamoxifen-related non-alcoholic fatty liver disease is in breast cancer patients, identify associated risk factors (notably BMI and hypercholesterolaemia), and assess regi…
DOI: 10.1111/liv.14434 -
Evaluation of postprandial hypoglycemia in patients with nonalcoholic fatty liver disease by oral glucose tolerance testing and continuous glucose monitoring
In biopsy-proven NAFLD patients, the study used 75-g oral glucose tolerance testing (OGTT) and continuous glucose monitoring (CGM) to characterize postprandial hypoglycemia, identifying its associations with low HbA1c, early glucose rise, low fasting/early insulin secretion, del…
DOI: 10.1097/meg.0000000000001118 -
Association of serum ferritin levels with non-alcoholic fatty liver disease in postmenopausal women
This cross-sectional study in postmenopausal Korean women shows that higher serum ferritin levels are independently associated with the presence of non-alcoholic fatty liver disease (NAFLD), suggesting ferritin as a potential marker for NAFLD risk in this population.
DOI: 10.1080/13697137.2018.1493451 -
Non-Alcoholic Steatohepatitis: What Can We Learn from Animal Models?
This article is a comprehensive narrative review of animal models used to study non-alcoholic steatohepatitis (NASH), detailing nutritional, genetic, and pharmacological approaches across multiple species, their advantages and limitations, and implications for understanding huma…
DOI: 10.2174/092986712799462586 -
Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score–matched cohort study
This study compares the risk of newly developed fatty liver and changes in serum lipid parameters between postmenopausal women with early breast cancer treated with tamoxifen versus aromatase inhibitors, finding a significantly higher incidence of fatty liver in the tamoxifen gr…
DOI: 10.1016/j.ejca.2017.05.002 -
Tamoxifen: a novel treatment for primary biliary cirrhosis?
This study presents two cases of patients with primary biliary cirrhosis who experienced a significant reduction in serum alkaline phosphatase levels while undergoing tamoxifen therapy, suggesting a potential therapeutic role for tamoxifen in this condition.
DOI: 10.1111/j.1478-3231.2004.00920.x -
Sex Differences in Choline-Deficient Diet-Induced Steatohepatitis in Mice
This study evaluated sex differences in methionine-choline deficient diet-induced steatohepatitis in C57BL/6J mice and tested whether ovariectomy or antiestrogen treatment (tamoxifen) modulates disease; findings show comparable liver injury in males and females, with ovariectomy…
DOI: 10.1177/153537020422900204 -
Cholesterol depletion by methyl-β-cyclodextrin augments tamoxifen induced cell death by enhancing its uptake in melanoma
Cholesterol depletion with methyl-β-cyclodextrin enhances tamoxifen-induced cell death in metastatic melanoma cells and reduces tumor growth in mice by increasing tamoxifen uptake and downregulating Cav-1 and Akt/ERK signaling.
DOI: 10.1186/1476-4598-13-204 -
Expression of steroid receptors in intact rat uterus, mammary gland, and liver treated with selective estrogen receptor modulators and conjugated equine estrogens
This study investigates the effects of conjugated equine estrogens (CEE) and selective estrogen receptor modulators (SERM) on the expression of estrogen and progesterone receptors in the intact rat uterus, mammary gland, and liver, revealing that CEE treatment significantly upre…
DOI: 10.1007/bf02849952 -
Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver
This study investigates tamoxifen-induced hepatic triglyceride accumulation in female rats with DMBA-induced mammary tumors, showing that it arises mainly from increased hepatic triacylglycerol biosynthesis with unchanged beta-oxidation/uptake/secretion, and demonstrates that co…
DOI: 10.1194/jlr.m600148-jlr200 -
54 Tamoxifen inhibits mitochondrial function, topoisomerases and mitochondrial DNA synthesis, and causes progressive mitochondrial DNA depletion and steatosis in mouse liver
This study investigates the impact of obesity and diabetes on liver-related death in a cohort of 963 patients with compensated alcoholic and viral cirrhosis, finding that overweight significantly increases the risk of liver-related mortality.
DOI: 10.1016/s0168-8278(05)81466-7 -
Evaluation of toxicities induced by chemotherapy in breast cancer patients
This study evaluates the toxicities induced by chemotherapy in breast cancer patients, comparing hematological and hepatic parameters between those treated with CMF, those treated with CMF and tamoxifen, and newly diagnosed patients who had not received chemotherapy.
DOI: 10.1016/j.biopha.2004.12.002 -
Effects of Tamoxifen vs. Toremifene on fatty liver development and lipid profiles in breast Cancer
A retrospective propensity-score matched cohort study in 308 early breast cancer patients shows tamoxifen increases the risk and severity of fatty liver and liver fibrosis and worsens certain lipid parameters, whereas toremifene favors better lipid profiles and lower fatty liver…
DOI: 10.1186/s12885-021-08538-5 -
Optimization of tamoxifen-induced Cre activity and its effect on immune cell populations
Tamoxifen dose and delivery route critically shape Cre activation across immune cell populations in a ubiquitous Cre/ER model, with oral 3 mg TAM for 5 days giving robust YFP induction with minimal toxicity, while higher doses or intraperitoneal delivery cause toxicity and tissu…
DOI: 10.1038/s41598-020-72179-0